Precision immunotherapies

Avidea is leveraging innovations in polymer-drug conjugate (PDC) technologies to develop safer and more effective immunotherapies for treating cancer, autoimmunity and infectious diseases.

Our technology

Avidea’s polymer-drug conjugate (PDC) platforms overcome key hurdles for enabling successful immunotherapies.

Learn more 


  • Modular vaccine capable of co-delivering any antigen(s) and immunomodulator(s) in self-assembling nanoparticles with precise size and composition
  • Most efficient T cell priming platform reported to-date
  • Applications: cancer, autoimmunity and infectious diseases


  • Synthetic, virus-sized star polymer combines direct tumor killing with immune stimulation, akin to oncolytic viruses, without the drawbacks
  • Dual responsive properties for targeted accumulation and selective drug release in tumor
  • Applications: metastatic tumor targeting


  • Nanoparticle formation occurs after injection thereby trapping drug in tissues where it is needed
  • Reduces dosing frequency in volume restricted tissue
  • Applications: retains drugs in the eye, CNS and joints

Our team

Our team is building on more than two decades of pioneering work by our world-class scientific founders and advisors who are experts in immunology, oncology, vaccines and biomaterials.


Avidea is looking for highly motivated and talented individuals to join our team. Check out our careers page to learn about opportunities to join our growing team.

Avidea's products are built on strong scientific principles

Scientific principles underlying technology platforms

In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.

Read more

Description of SNAPvax as a platform for promoting T cell immunity

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Read more

Immunological mechanisms for enhanced efficacy by intravenous vaccination

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.

Read more

Avidea in the news

December 13, 2021
November 1, 2021

Avidea CEO to present updates on SNAPvax programs at the Vaccines R&D meeting in Baltimore on November 2nd and at the Festival of Biologics in Basel, Switzerland on November 10th.

September 13, 2021

Avidea Expands Scientific Advisory Board with Appointment of Prof. Dan Barouch, MD, PhD


June 14, 2021

Avidea’s SNAPvaxTM Tolerance Vaccine Program Boosted by SAB Appointments and Encouraging Preclinical Data